PODD Stock Price Today (July 2026) — Insulet Corporation Analysis & Key Metrics 2026-07-17
Insulet Corporation (PODD) is trading at $164.06, down 0.23% today (as of July 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $240.25 (46.4% upside).
- Volatility remains elevated (32.07% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (33.90% YoY) alongside significant competitive pressures.
PODD Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Insulet Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $11.08B
P/E Ratio
Forward P/E: 19.67
Revenue Growth
Year over Year
Analyst Target
+46.4% upside potential
Key Investor Questions About PODD
What investors need to know before buying
Based on current market data, PODD presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 59.74)
- Fundamentals say: Caution warranted (high leverage concerns)
PODD's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PODD investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $1.01B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, PODD stock traded between $138.79 and $354.88—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.07% annualized volatility and β=0.69, the stock exhibits low sensitivity to market moves—making PODD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
3 Quality Compounders on Our Buy List
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.
Insulet Corporation (PODD) Fell Along with Broad Medtech Sector
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]
Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
DXCM Grew. The Stock Did Not. Someone Is Wrong
The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.
Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%
Insulet stock has fallen sharply over the past year, yet the valuation checks still lean toward the shares being on the expensive side rather than a clear bargain. Insulet is down 46.8% over the past year, which means anyone looking at the stock today is doing so after a significant reset in the share price. On the one hand, growth expectations around the Omnipod franchise may support the current price. On the other hand, class action lawsuits and an FDA Class I recall highlight product and...
Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?
Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, adding another European market to its footprint. See our latest analysis for Insulet. Despite the positive headlines from Spain, Insulet’s share price return over the past year has declined 46.78% on a total shareholder return basis, with shorter term share price momentum also weaker. This suggests investors are still...
Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM
By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Insulet Corporation (NASDAQ:PODD) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares. The adjustment […]
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain
PODD expands Omnipod 5 to Spain, marking its 20th country launch and adding Omnipod Discover to strengthen digital diabetes care.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.
Frequently Asked Questions
Common investor questions about Insulet Corporation
Insulet Corporation (PODD) is currently trading at $164.06. The RSI (14-day) is at 59.7, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $240.25 implies 46.4% upside from current levels. Volatility is moderate at 32.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insulet Corporation (PODD): The trailing P/E ratio is 38.33, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.67, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 8.72. Price-to-Sales is 3.92. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering PODD, the consensus price target is $240.25. This represents a 46.4% upside from the current price of $164.06. The range spans from a low target of $165.00 to a high target of $360.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insulet Corporation (PODD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insulet Corporation (PODD) investors include: 1. Moderate volatility (32.1% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insulet Corporation's (PODD) current debt and financial health profile: Total debt stands at $1.01B. The debt-to-equity ratio is 77.84, which is moderate and generally manageable for most companies. The current ratio is 2.49, indicating strong short-term liquidity. The quick ratio is 1.49. The company holds $480.40M in cash and equivalents. Free cash flow is positive at $253.38M, providing a cushion for debt servicing and shareholder returns.